Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385631 | 1.00 | TRPA1 (0.40) | TRPA1MAPTLMNAPGRCYP3A4 | |
| SCHEMBL3398907 | 1.00 | TRPA1 (0.40) | TRPA1MAPTLMNAPGRCYP3A4 | |
| SCHEMBL3392105 | 1.00 | TRPA1 (0.40) | TRPA1MAPTLMNAPGRCYP3A4 | |
| SCHEMBL3390303 | 1.00 | TRPA1 (0.40) | TRPA1MAPTLMNAPGRCYP3A4 | |
| SCHEMBL3392881 | 1.00 | TRPA1 (0.40) | TRPA1MAPTLMNAPGRCYP3A4 | |
| SCHEMBL25223417 | 0.84 | TRPA1 (0.38) | TRPA1MAPTALOX15 | |
| SCHEMBL25222905 | 0.83 | LMNA (0.38) | MAPTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL25217163 | 0.83 | LMNA (0.38) | MAPTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL25271559 | 0.83 | LMNA (0.38) | MAPTLMNAPGRCYP3A4CYP2D6 | |
| SCHEMBL25274021 | 0.83 | TRPA1 (0.41) | TRPA1MAPTLMNAPDE3ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255903-A1 | URINARY SYMPTOM THERAPEUTIC AGENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-08-17 | — | — | US | claimed |
| EP-4176873-A1 | URINARY SYMPTOM THERAPEUTIC AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-05-10 | — | — | EP | claimed |
| CN-115715191-A | Therapeutic agent for urination symptom | 大鹏药品工业株式会社 | 2023-02-24 | — | — | CN | claimed |
| WO-2022004867-A1 | URINARY SYMPTOM THERAPEUTIC AGENT | 大鵬薬品工業株式会社 | 2022-01-06 | — | — | WO | claimed |
| EP-3332779-B1 | AMELIORATING AGENT FOR DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-10-28 | — | — | EP | claimed |
| EP-3332779-A1 | AMELIORATING AGENT FOR DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-06-13 | — | — | EP | claimed |
| EP-2853261-B1 | Agent for improving vesicourethral dyssynergia | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-11-01 | — | — | EP | claimed |
| US-20170252307-A1 | DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | claimed |
| US-9687457-B2 | Detrusor hyperactivity with impaired contractility ameliorating agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-27 | — | — | US | claimed |
| US-20170035706-A1 | DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-09 | — | — | US | claimed |
| EP-2853261-A1 | Agent for improving vesicourethral dyssynergia | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-04-01 | — | — | EP | claimed |
| EP-1839653-B9 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-12-22 | — | — | EP | claimed |
| EP-2196200-A1 | Cyclohexenone derivative for treating or preventing hypesthesia or hyperesthesia caused by diabetes | Meiji Dairies Corporation (JP) | 2010-06-16 | — | — | EP | claimed |
| EP-1839653-B1 | THERAPEUTIC AGENT FOR SENSORY DISORDERS | MEIJI DAIRIES CORP (JP) | 2010-06-09 | — | — | EP | claimed |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | MEIJI CO., LTD (JP) | 2009-03-12 | — | — | US | claimed |
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | UNIVERSITE DE STRASBOURG (FR) | 2008-12-18 | — | — | US | claimed |
| EP-1839653-A1 | THERAPEUTIC AGENT FOR SENSORY ABNORMALITY | Meiji Dairies Corporation (JP) | 2007-10-03 | — | — | EP | claimed |
| US-6906107-B2 | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria | MEIJI DAIRIES CORPORATION (JP) | 2005-06-14 | — | — | US | claimed |
| EP-1003706-B1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME | MEIJI MILK PROD CO LTD (JP) | 2003-03-05 | — | — | EP | claimed |
| US-6228893-B1 | TREATING DEMENTIA | MEIJI MILK PRODUCTS CO., LTD. (JP) | 2001-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035706-A1 | DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENT | BPHL, QDPR, PDE12 | TRPA1 1103/4885MAPT 1979/4885LMNA 2700/4885 |
| US-20080312336-A1 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder | CPT1B, CHRM1, ADRA1D | TRPA1 2967/4885MAPT 4599/4885LMNA 785/4885 |
| US-20230255903-A1 | URINARY SYMPTOM THERAPEUTIC AGENT | REN, BPHL, PDE12 | TRPA1 177/4885MAPT 1373/4885LMNA 4000/4885 |
| US-20170252307-A1 | DETRUSOR HYPERACTIVITY WITH IMPAIRED CONTRACTILITY AMELIORATING AGENT | BPHL, QDPR, DBH | TRPA1 770/4885MAPT 2083/4885LMNA 2449/4885 |
| US-20090069442-A1 | Therapeutic Agent for Sensory Abnormality | PMP22, NGF, HRH1 | TRPA1 13/4885MAPT 3594/4885LMNA 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.